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NeurostimulationPrevious studies investigated fMRI-guided repetitive TranscranialMagnetic Stimulation (rTMS) as an alternative
treatment for auditory verbal hallucinations (AVH). This tailor-made treatment focuses at directing the rTMS coil
to the locationwhere hallucinatory activation ismaximal, as identiﬁedwith fMRI scans of individual patients. For
the effective use of such treatment it is important to determine whether brain activation during AVH can be
reliably detected using fMRI. Thirty-three psychotic patients indicated the presence of AVH during two subse-
quent scans. Reproducibility was measured by calculating 1) the distance between local maxima of signiﬁcantly
activated clusters and 2) percentage overlap of activation patterns over the two scans. Thesemeasurementswere
obtained both in single subjects and on group-level in ﬁve regions of interest (ROIs). ROIs consisted of the areas
that were most frequently activated during AVH. Scans were considered reproducible if the distance between
local maxima was smaller than 2 cm, as rTMS-treatment may target an area of approximately 2–4 cm. The
median distance between local maxima was smaller than 2 cm for all ROIs on single-subject level, as well as
on group-level. In addition, on single-subject level median percentage overlap varied between 14 and 38% for
the different ROIs. On group-level, this was substantially higher with percentages overlap varying between 34
and 98%. Based on these results, AVH-scans may be considered sufﬁciently reproducible to be suitable for
fMRI-guided rTMS treatment.
© 2013 Elsevier B.V. All rights reserved. Open access under the Elsevier OA license.1. Introduction
The development of functional imaging techniques capable of
“symptom-capturing” (i.e., capturing brain activation related to a symp-
tom) has enabled the start of individual tailor-made treatments of
psychiatric or neurological symptoms. An example of this strategy is
the focal treatment of auditory verbal hallucinations (AVH) with repet-
itive Transcranial Magnetic Stimulation (rTMS) or experimental treat-
ment such as invasive electrocortical stimulation. A major advantage
of these tailor-made treatments is that they have the potential to treat
medication-resistant symptoms such as AVH, tics, tremor or obsessions.
At present, the primary treatment for AVH consists of antipsychotic
medication which is often combined with cognitive behavioral therapy.
Although antipsychotic medication is largely effective in treating hallu-
cinations, AVH do not respond to antipsychotic medication in 25–30%
of schizophrenia patients. Repetitive Transcranial Magnetic Stimulation
(rTMS) is a noninvasive method for altering activation of cortical neu-
rons by rapidly changing magnetic ﬁelds. RTMS is a safe treatment
method with only mild side effects such as transient headache andDevelopment and Neuroscience,
dge, UK. Tel.: +44 1223339544;
.
evier OA license.scalp discomfort during stimulation (Slotema et al., 2012) which may
be a treatment option for AVH in patients with insufﬁcient response to
pharmacotherapy. Most studies, thus far, have applied low frequency
rTMS for the treatment of hallucinations. Although the exactmechanism
by which low frequency rTMS may improve AVH remains elusive, it is
thought that when stimulation with rTMS is applied repeatedly, the
targeted area becomes less active for a longer period, i.e., decreasing
hallucinatory hyperactivation.
Although three large RCTs published recently failed to show a sig-
niﬁcant effect of rTMS in comparison to placebo-controlled treatment
(Vercammen et al., 2009; Loo et al., 2010; Slotema et al., 2010),
meta-analyses reported a signiﬁcant effect of rTMS as compared to
placebo on the treatment of AVH with mean weighted effect sizes
ranging from 0.33 to 1.0 (Aleman et al., 2007; Tranulis et al., 2008;
Freitas et al., 2009; Slotema et al., 2010, 2012).
Most studies applying rTMS in the treatment of AVH targeted a ﬁxed
position on the skull corresponding to the left temporoparietal area
(Slotema et al., 2012). The rationale for selecting this area is that it over-
lies speech perception areas, hyperactivation of which has been hypothe-
sized to be involved in the occurrence of AVH. While treatment of this
area seems to result in a decrease in the severity of AVH, a number of
fMRI studies showed that activation patterns duringAVH tend to vary sig-
niﬁcantly among individual patients as in approximately one-half of the
patients activation during AVH can be observed in right-hemispheric
Table 1
Demographic data of the participants.
Group 1: reliability
analyses (N=33)
Group 2: to deﬁne
ROIs (N=30)
Mean Mean
Age (years) 39.28 (SD=10.15) 39.6 (SD=10.01)
Age (years) at onset AVH 19 (SD=19) 21 (SD=11)
Gender
Females 19 14
Males 14 16
Handedness
Right-handed 26 26
Not right-handed 6 4
Diagnosis
Schizophrenia 22 23
Schizo-affective disorder 3 1
Psychosis NOS 6 4
Personality disorder and
psychosis NOS
1 0
Borderline personality
disorder and psychosis NOS
1 1
One-time depressive period 0 1
Medication
Antipsychotic
No antipsychotics 4 6
Typical antipsychotics 10 7
Atypical antipsychotics 18 15
Combi typical & atypical
antipsychotics
1 1
PANSS scores
Total 67 (SD=15) 70 (SD=15)
Positive subscale 16 (SD=4) 18 (SD=4)
Negative subscale 18(SD=5) 18 (SD=6)
Abbreviations: AVH, auditory verbal hallucinations; N, number; SD, standard deviation;
NOS, not otherwise speciﬁed; and PANSS, Positive and Negative Syndrome Scale.
321K.M.J. Diederen et al. / Schizophrenia Research 146 (2013) 320–325areas, i.e., the right temporoparietal and inferior frontal area, homologous
to Broca's area of language production (Sommer et al., 2007; Sommer et
al., 2008). Initial reports from studies targeting other areas than the left
temporoparietal regiondo, however, not showsuperior or even compara-
ble effects. While Lee et al. (2005) reported reductions in severity of AVH
after rTMS directed at the right temporoparietal region, this was not rep-
licated by others (Jandl et al., 2006; Loo et al., 2010). In addition, repetitive
TMS treatment of the bilateral temporoparietal regions revealed no sig-
niﬁcant differences in comparison with placebo treatment (Vercammen
et al., 2009; van Lutterveld et al., 2012). Finally, stimulation of Broca's
area or the left superior temporal gyrus (Schonfeldt-Lecuona et al.,
2004) was no more effective than sham treatment. It should, however,
be noted that the lack of efﬁcacy of rTMS directed at more frontally
located areas, such as Broca's area, might be due to the facial muscula-
ture overlying the skull in this area. Because rTMS can only reach a
depth of 1–2 cm, additional muscle layers might prevent the rTMS
pulse from affecting Broca's area (Hoffman et al., 2007; Slotema et al.,
2012). Moreover, only few studies targeted other areas than the left
temporoparietal area and the superior effects of this area as compared
to other areasmay result mainly from lacking power to support efﬁcacy
of rTMS targeted at other areas.
As maximum activation during AVH varies over patients a more suit-
able approach might be to identify areas where hallucinatory activation
is maximal on a single subject-level and use these foci as the target for
rTMS treatment (Sommer et al., 2007). While this tailor-made approach
has proved to be feasible, only three studies have thus far investigated
fMRI-guided rTMS inmultiple patients of which just two studies directly
compared guided to non-guided rTMS. Hoffman et al. (2007) used a de-
sign in which the ﬁrst ﬁve patients were treated with rTMS targeted at
three sites where hallucinatory activation was maximal or brain areas
that showed signiﬁcant correlation with the timecourse in Wernicke's
area during AVH. In the remaining patients up to six active sites could
be targeted with rTMS. Statistically greater rates of improvements in
AVH were observed when rTMS was directed to left temporoparietal
sites compared to anterior temporal sites and sham stimulation. Enabling
a direct comparison between guided andnon-guided rTMS Sommer et al.
(2007) treated seven patients with guided rTMS while six patients re-
ceived non-guided rTMS. Although no signiﬁcant difference could be ob-
served upon the frequency of AVH, fMRI-guided rTMS appeared superior
at trend level to non-guided rTMS in decreasing severity of general psy-
chosis. While this argues for the use of fMRI guided rTMS treatment the
largest study to date revealed that the effects of fMRI-guided rTMS
(and left temporoparietal rTMS) on the severity of AVHwere comparable
to those of sham treatment (Slotema et al., 2010). Although these results
should be treated with caution, a reason for these negative ﬁndings
might be that brain activation during AVH cannot be reliably detected
using fMRI. This is crucial for optimal treatment as scans that are
unreliablemay not reﬂect the true substrate of interest andwill therefore
be less effective when used as the main source for treatment guidance.
The aim of the present study was therefore to investigate spatial repro-
ducibility of AVH-related brain activation both at the individual and at
the group level. To circumvent the inﬂuence of factors that are difﬁcult
to keep constant with increased time between measurements, such as
arousal, medication and caffeine-intake, reproducibility was investigated
between two AVH-sessions acquired within the same visit.
2. Materials and methods
2.1. Subjects
Thirty-three psychotic patientswithmedication-resistant AVHwere
recruited from the University Medical Center Utrecht and the Parnassia
Bavo Group in The Hague, The Netherlands. Patients were selected for
participation from a larger group of patientswith chronic hallucinations
(Slotema et al., 2011) if theymet the following criteria: (1) the presence
of two subsequent AVH scans in which (2) intermittent AVH wereexperienced (i.e., AVH alternated with non-AVH state), (3) at least
three AVH-episodes were present per scan (4) and AVHwere indicated
correctly (i.e., AVH-onsetswere followedby clear offsets). Patientswere
diagnosed using the Comprehensive Assessment of Symptoms and
History (CASH) (Andreasen et al., 1992) interview according to DSM-IV
criteria by an independent psychiatrist. Demographic and clinical data
of the participants is provided in Table 1.
2.2. Data acquisition
Participants indicated the presence of AVH by balloon-squeezeswhile
scans were acquired continuously. Data acquisition was similar for all
AVH-scans and took 8 min per scan. Imageswere obtained using a Philips
Achieva 3 Tesla Clinical MRI scanner. An AVH scan consisted of a series of
blood-oxygenation-level-dependent T2* weighted images over time.
PRESTO-SENSE was used to acquire the T2* weighted fMRI images, opti-
mally using parallel imaging and echo shifting to reduce acquisition
time of up to 609 ms/volume (Neggers et al., 2008). Eight hundred
PRESTO-SENSE images were acquired per session (40 slices, TR/TE
21.75/32.4 ms, ﬂip angle 10°, ﬁeld of view 224×256×160, matrix 64×
64×40, voxelsize 4 mm isotropic, acquisition time 609 ms/volume). To
improve localization of functional data, a high-resolution anatomical
scan was conducted in addition to the AVH-scans (TR/TE: 9.86/4.6 ms,
1×1×1 voxels, ﬂip angle 8°, FOV 224×160×168.00, 160 slices).
2.3. Data analysis
Preprocessing and analysis were conducted with Statistical Para-
metric Mapping (SPM5; Welcome Department of Cognitive Neurolo-
gy, London, UK) and included the following steps: realignment,
coregistration, spatial normalization and smoothing, using an 8-mm
full width at half maximum Gaussian kernel. Scans were analyzed
on a voxel by voxel basis using multiple regression analysis with
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This model was convolved with the hemodynamic response function
from SPM5 to introduce typical delays of fMRI responses and ﬁtted to
the data using general linear model estimation (Worsley and Friston,
1995). Data was high-pass ﬁltered with a cutoff of 100 s. and temporal
autocorrelation was modeled with an autoregressive model of the ﬁrst
order (AR(1)).
2.4. Selection regions of interest
Reproducibility analyses were conducted on whole brain level and
within ﬁve regions of interest (ROIs). ROIs were identiﬁed with the aid
of a separate fMRI experiment in which brain activation during AVH
was investigated in a group of thirty psychotic patients. The same inclu-
sion criteria and experimental procedure was used as for the reproduc-
ibility analysis. In addition, the group included for this analysis was
rather similar with respect to diagnoses and demographical characteris-
tics to the group participating in the reproducibility analyses. Table 1
provides data on patients included in the reproducibility analyses as
well as the analyses to identify the ROIs. First, a one-sample T-test was
conducted to detect clusters displaying signiﬁcant activation during
AVHon group-level. Of each cluster, themost signiﬁcant localmaximum
(i.e. voxel with the highest T-value) was identiﬁed and ROIs were then
created by drawing 16 mm spheres centered on these local maxima.
For this analysis, a threshold of p=0.05 whole-brain false discovery
rate (FDR) corrected for multiple comparisons, was used. Cluster sizes,
p-values, t-values and locations of localmaxima for brain activation dur-
ing AVH in this group are displayed in Table 2.
This analysis revealed signiﬁcant activation inﬁve brain areas (leading
to ﬁve ROIs for later reproducibility analyses) comprising the left tempo-
roparietal region, the right inferior frontal region, the middle superior
frontal region and the left motor region, as well as the right cerebellum.
Activation of these regions during AVH is in concordance with previous
reports (Sommer et al., 2008; Diederen et al., 2010, 2012). Activation of
two of these areas, the motor region and cerebellum might be related to
balloon-squeezes used to indicate the AVH (Sommer et al., 2008), rather
than to the actual AVH.
2.5. Reproducibility analysis
Spatial reproducibility was measured by determining 1) Euclidian
distance between localmaxima and 2) Percentage overlap of signiﬁcant
activity between both hallucination scans. Percentage overlap ‘PO’ was
calculated with the Jaccard similarity coefﬁcient (Maitra, 2010) by
dividing the number of overlapping voxels during AVH-scan 1 and
AVH-scan 2 ‘AVH1,2’ by the amount of uniquely activated voxels for
both sessions ‘(AVH1+AVH2)−(AVH1,2)’ as expressed by the formula:
PO ¼ AVH1;2ð Þ
AVH1þ AVH2ð Þ− AVH1;2ð Þ  100:Table 2
Cluster sizes, p-values, T-values and locations of local maxima for brain activation during
AVH.
Regions of interests (ROIs) MNI coordinates z-score p-value Cluster
size
X Y Z
Left temporoparietal area (lTP) −52 −24 24 3.54 0.036 63
Right inferior frontal area (rIF) 56 12 4 3.42 0.037 25
Middle superior frontal area
(mSF)
0 4 52 3.39 0.038 36
Left motor area (lMA) −36 −28 52 4.11 0.024 131
Right cerebellum (rCB) 24 −52 −24 4.07 0.024 63
Threshold: p=0.05 whole-brain false discovery rate (FDR) corrected for multiple
comparisons.
Abbreviations: MNI, Montreal Neurological Institute.Percentage overlap was calculated on whole brain level and within
ﬁve ROIs (i.e. the ﬁve ROIs selected from a separate fMRI experiment;
see selection regions of interest). Distance between local maxima was
only calculated within ROIs. If multiple signiﬁcant local maxima could
be observed within an ROI, the local maximum with the highest
T-value was selected.
Analyses were conducted on single subjects and on group-level. On
single-subject level, subjects with no signiﬁcant activation in at least
one AVH-scan were excluded from the peak distance analysis. Individ-
uals with no signiﬁcant activation in both AVH-scans were excluded
from percentage overlap analysis. This was determined with the aid of
a one sample t-test, per scan, per subject, with a threshold of p=0.05,
FDR corrected for all voxels within an ROI or on whole-brain level. The
same threshold was used for reproducibility analyses.2.6. Reproducibility criterion
As rTMS may target an area of approximately 2–4 cm, scans were
considered suitable for fMRI-guided rTMS-treatment if the distance
between local maxima was smaller than 2 cm (Wagner et al., 2008).
For more focal treatments such as invasive electrocortical stimulation
and deep brain stimulation no exact criterion was speciﬁed, however,
the area that may by targeted by these techniques is expected to be in
the millimeter range (Miglioretti and Boatman, 2003).3. Results
3.1. Performance data
The average number of AVHwas 25 (SD 25) for theﬁrst hallucination
scan and24 (SD 34) for the second hallucination scan. The average dura-
tion of a hallucination was 13 (SD 29) seconds in scans 1 and 17 (SD 41)
in scan 2, adding up to a mean total duration of hallucinations of 148
(SD 120) seconds in scan 1 and 170 (SD 178) seconds in scan 2.
No signiﬁcant differences were found for the number of AVH
(T (32)=0.41, p=0.68), the total duration of the AVH (T (32)=−1.12,
p=0.27) and the average durationof theAVH(T (32)=−1.54, p=0.14)
between the two sessions.3.2. Amount of signiﬁcantly activated voxels
Except for the left temporoparietal region thenumber of signiﬁcantly
activated voxels did not differ signiﬁcantly between the two scans. On
group-level, all ROIs displayed a somewhat higher number of signiﬁ-
cantly activated voxels for scan 1 compared to scan 2. This was also
found on whole brain level (see Table 3).3.3. Peak distance
3.3.1. Single-subject level
On single-subject level, distance between local maxima was below
the predeﬁned cutoff of 2 cm in all regions. It was smallest for the
middle superior frontal area (2 mm), followed by the right inferior
frontal area (4 mm), the cerebellum (6 mm), the left motor area
(7 mm) and the left temporoparietal area (13 mm) (see Table 3 and
Fig. 1).3.3.2. Group-level
On group-level, distance between local maxima was also below the
predeﬁned criterion of 2 cm for all regions. It was 12 mm for the right
inferior frontal area, 18 mm for the left motor area, 7 mm for the left
temporoparietal area, 13 mm for the middle superior frontal area and
12 mm for the right cerebellum (see Table 3).
Table 3
Number of voxels signiﬁcantly activated in the two AVH-scans, percentage overlap and distance between local maxima for the two AVH-scans.
N voxels1 N voxels2 Statistics % Overlap Peak distance
Median Range Median Range N voxels 1 vs N voxels 2 Median Range Median Range
Single-subject
lTP 137 9–243 74 1–240 Z=−2.930, p=0.003* 31% 0–97% 13 mm 0–22 mm
lMT 134 10–220 90 0–220 Z=−0.237, p=0.813 23% 0–68% 7 mm 0–22 mm
rIF 68 0–161 71 0–166 Z=−0.168, p=0.866 25% 6–68% 4 mm 0–19 mm
mSF 111 0–242 117 0–244 Z=−0.264, p=0.792 38% 0–96% 2 mm 0–23 mm
rCB 70 3–237 109 11–242 Z=−1.354, p=0.176 14% 0–96% 6 mm 0–17 mm
WB 600 5–6121 300 6–6926 Z=−0.884, p=0.376 22% 0–61%
Total Total Total Total
Group-level
lTP 207 136 82% 7
lMT 221 192 95% 18
rIF 147 138 98% 12
mSF 161 105 76% 13
rCB 193 83 63% 12
WB 7304 2560 34%
Abbreviations: lTP, left temporoparietal area; lMT, left motor area; rIF, right inferior frontal area; mSF, middle superior frontal area; rCB right cerebellum; WB, whole brain and N,
number.
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3.4.1. Single-subject level
On single subject-level, median percentage overlap was highest for
the middle superior frontal area (38%), followed by the left tempo-
roparietal area (31%); the right inferior frontal area (25%), the left
motor area (23%), whole brain (22%) and the right cerebellum (14%)
(see Table 3 and Fig. 2).
3.4.2. Group-level
On group-level, percentage overlap was 98% for the right inferior
frontal area, 95% for the leftmotor area, 82% for the left temporoparietal
area, 76% for the middle superior frontal area, 63% for the right cerebel-
lum and 34% on whole brain level (see Table 3 and Fig. 3).
4. Discussion
This study investigated spatial reproducibility of brain activation dur-
ing auditory verbal hallucinations (AVH) to evaluate whether symptom
capture scans can be used for fMRI-guided tailor-made focal treatments.
Reproducibility was assessed with distance between local maxima and
percentage overlap as the main measurements.
The median distance between local maxima was smaller than 2 cm
for all ROIs on single-subject, as well as on group-level. In addition, onFig. 1.Within-subject distance between signiﬁcant local maxima in scan 1 versus scan
2. Abbreviations: lTP, left temporoparietal area; lMT, left motor area; rIF, right inferior
frontal area; mSF, middle superior frontal area and rCB right cerebellum.single subject level, percentage overlap was between 14 and 38% in all
regions of interest (ROIs). On group-level, this was much higher with
a percentage overlap of 98% in the most reproducible ROI.
Based on our criterion for reproducibility of less than 2 cm distance
between the local maxima, these scans can be considered suitable for
fMRI-guided rTMS-treatment. However, it is important to note that in
the left temporoparietal area, which corresponds with the region most
frequently targeted in the treatment of AVH (Slotema et al., 2010),
over 25% of individuals displayed a median distance of more than
2 cm (see Fig. 1) between local maxima. Furthermore, the median per-
centage overlap was below 40% in all ROIs. In addition, our measure of
individual variability should be seen as a lower bound of reproducibility,
as in this study reproducibility was investigated between two AVH-
scans acquiredwithin the same fMRI session to circumvent the inﬂuence
of factors that are difﬁcult to keep constantwith increased time between
measurements, including arousal, medication and caffeine-intake.
Although we did not set criteria for other focal treatments such as in-
vasive electrocortical stimulation it is highly questionable if hallucination
scans can be considered suitable for guiding these treatments as the areas
that may be targeted by these techniques are expected to be within the
millimeter range (Miglioretti and Boatman, 2003).
This is the ﬁrst study to investigate reproducibility of AVH-related
brain activation. However, fMRI-reliability was previously studied in
relation to motor and visual tasks, as well as during various cognitiveFig. 2. Within-subject percentages overlap. Abbreviations: lTP, left temporoparietal
area; lMT, left motor area; rIF, right inferior frontal area; mSF, middle superior frontal
area; rCB right cerebellum and WB, whole brain.
Fig. 3. Brain regions signiﬁcantly activated onwhole brain level andwithin ROIs in AVH-scan 1 andAVH-scan 2 of the group-wise analysis. a.Whole brain, b. left temporoparietal area, c. left
motor area, d. right inferior frontal area, e.Middle superior frontal area and f. right cerebellum. Threshold: p=0.05, false discovery rate corrected formultiple comparisonswithin ROIs or on
whole-brain level.
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2000; Manoach et al., 2001; Raemaekers et al., 2007; Zandbelt et al.,
2008; Bennett andMiller, 2010). While percentage overlap is frequently
used to investigate reproducibility, distance between local maxima is
not a standard measure. Recently, Bennett and Miller (2010) reviewed
fMRI-reliability studies and reported an average percentage overlap,
calculated with the Jaccard coefﬁcient, of 33% when the test and retest
scans took place within the same hour. This is rather similar to the per-
centage overlap observed in this study which ranged between 14 and
38% on single-subject level. Bennett and Miller (2010) also showed thatmost studies observed a higher percentage overlap on group-level than
on single-subject level which is in line with the ﬁndings of the current
study.
4.1. Limitation
Themain limitation of themetrics employed in this study, especially
percentage overlap, is the dependence on the selected signiﬁcance
threshold (Manoach et al., 2001). Moreover, with respect to the repro-
ducibility criterion adopted for rTMS a limitation is that the size of the
325K.M.J. Diederen et al. / Schizophrenia Research 146 (2013) 320–325area targeted by rTMS depends on a number of factors including coil
geometry and orientation (Kammer et al., 2007). As a result, our criterion
of 2 cmmight be appropriate for themost commonly used coils, namely
the ﬁg. of 8 coil, but not for others such as the H-coil.
5. Conclusion
In summary, as the median distance between local maxima on indi-
vidual scans was smaller than 2 cm in all ROIs, these scans may be con-
sidered sufﬁciently reproducible and hence suitable for fMRI-guided
rTMS treatment. These results should, however, be treatedwith caution
as reproducibility was measured within one scan session and may
therefore represent a lower bound of reproducibility. For invasive
electrostimulation, however, higher percentage of overlap and lower
medium distance between local maxima are required.
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